See the DrugPatentWatch profile for Tresiba
The generic name for Tresiba is insulin degludec [1].
What is Insulin Degludec Used For?
Insulin degludec is a long-acting insulin used to improve glycemic control in adults and children aged one year and older with diabetes mellitus [1]. It is designed to provide a stable and predictable basal insulin profile [2].
How Does Insulin Degludec Work?
Insulin degludec is an ultra-long-acting basal insulin. It forms soluble multihexamers in the subcutaneous tissue, which then slowly dissociates into monomeric insulin, providing a continuous and prolonged effect [3]. This mechanism differs from other basal insulins and contributes to its extended duration of action [4].
When Does Insulin Degludec Go Generic?
The patent exclusivity for insulin degludec is a key factor in its generic availability. Information on patent expiry dates for specific drugs can be found on resources like DrugPatentWatch.com [5]. For instance, while the initial patent protection for Tresiba may expire at certain dates, subsequent patents or exclusivities related to formulation or manufacturing processes can extend market protection [6].
What Are the Side Effects of Insulin Degludec?
The most common side effect associated with insulin degludec, like other insulins, is hypoglycemia (low blood sugar) [1]. Other potential side effects include injection site reactions, lipodystrophy, and allergic reactions [7].
How Does Insulin Degludec Compare to Other Basal Insulins?
Insulin degludec offers an ultra-long duration of action, typically exceeding 24 hours, which may provide more dosing flexibility compared to other basal insulins like insulin glargine or insulin detemir [4]. Clinical studies have investigated its efficacy and safety in comparison to these other agents [3][4].
Who Makes Tresiba?
Tresiba is manufactured by Novo Nordisk [1].
What is the Cost of Insulin Degludec?
The cost of insulin degludec can vary based on factors such as insurance coverage, pharmacy pricing, and geographic location. Generic versions, when available, typically offer a lower price point than the branded product [5].
What Are the Risks Associated with Insulin Degludec?
Beyond hypoglycemia, potential risks include allergic reactions and the possibility of developing lipodystrophy (changes in fat tissue) at injection sites if rotation is not practiced [1][7]. It is crucial for patients to be educated on recognizing and managing these risks [7].
Sources:
[1] https://www.drugs.com/tresiba.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375838/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741478/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843461/
[5] https://drugpatentwatch.com/
[6] https://www.biospace.com/article/tresiba-insulin-degludec-patient-information-side-effects-and-dosage-101706177/
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba